Medline stock pops 20% in early trading after raising $6.3 billion in year's biggest IPO

Medline surged more than 30% on its market debut after pricing its IPO at $29 a share, raising $6.26 billion from roughly 216 million shares and implying a valuation north of $50 billion; the offering is the largest of the year and follows a 2021 buyout by Blackstone, Carlyle and Hellman & Friedman that valued the company at $30 billion. The deal caps the strongest year for IPOs since 2021 and comes amid growing optimism about large public listings ahead—SpaceX is reportedly positioned for a potential 2026 IPO at an implied $800 billion valuation, OpenAI and Anthropic are said to be weighing listings within 18 months, and Databricks, now valued at about $134 billion, could pursue an offering as soon as next year—signaling robust demand for major tech and enterprise issuers.

Analysis

Medline's IPO priced at $29 and raised $6.26 billion from roughly 216 million shares, with the stock jumping over 30% on its first trading day and implying a market value north of $50 billion. The pricing and strong debut make this the largest US IPO of the year and mark one of the highest-profile listings as markets close out the year.

The outcome represents a material re‑rating since the 2021 private equity transaction in which Blackstone, Carlyle and Hellman & Friedman acquired a majority stake at a reported $30 billion valuation; the IPO implies substantially higher public-market pricing power for Medline. The article notes a clarified role for Carlyle and Hellman & Friedman in the 2021 deal, underscoring private owners’ ability to monetize at expanded multiples in the current IPO window.

Market practitioners should view the deal as a confirmation of renewed appetite for large-scale issuers: the piece cites optimism for further mega listings (SpaceX reportedly eyed for 2026 at an $800 billion implied value, OpenAI and Anthropic reportedly exploring IPOs within 18 months, and Databricks at a $134 billion private valuation potentially going public next year). Sentiment and market-impact metrics in the report are strongly positive, but large first-day pops also signal potential for elevated aftermarket volatility and supply as insiders lock in gains.

Key Decisions for Investors

• Consider selectively participating in primary allocations for well-capitalized, sector-leading IPOs given evident buyer demand but keep position sizes disciplined due to likely short‑term volatility
• Reassess valuations relative to recent private rounds — Medline's implied >$50 billion versus the $30 billion 2021 buyout suggests a significant re-rating that should be justified by fundamentals before adding exposure
• Monitor the pipeline of mega listings (SpaceX, OpenAI, Anthropic, Databricks) as potential market catalysts and adjust liquidity and hedges ahead of pricing events, while avoiding reliance on first‑day pops as the sole basis for investment decisions